Rheumatoid Arthritis

You have free access to this content

The role of sleep problems in central pain processing in rheumatoid arthritis†

  1. Yvonne C. Lee1,‡,*,
  2. Bing Lu1,
  3. Robert R. Edwards1,
  4. Ajay D. Wasan1,
  5. Nicholas J. Nassikas1,
  6. Daniel J. Clauw2,§,
  7. Daniel H. Solomon1,¶,
  8. Elizabeth W. Karlson1

Article first published online: 27 DEC 2012

DOI: 10.1002/art.37733

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 65, Issue 1, pages 59–68, January 2013

Additional Information

How to Cite

Lee, Y. C., Lu, B., Edwards, R. R., Wasan, A. D., Nassikas, N. J., Clauw, D. J., Solomon, D. H. and Karlson, E. W. (2013), The role of sleep problems in central pain processing in rheumatoid arthritis. Arthritis & Rheumatism, 65: 59–68. doi: 10.1002/art.37733

Author Information

  1. 1

    Brigham and Women's Hospital, Boston, Massachusetts

  2. 2

    University of Michigan, Ann Arbor

  1. ‡

    Dr. Lee owns stock or stock options in Merck, Novartis, and Elan and has received research grants from Forest Research Institute.

  2. §

    Dr. Clauw has received consulting fees from Jazz Pharmaceuticals, Pfizer, Eli Lilly, Forest Laboratories, Pierre Fabre Pharmaceuticals, UCB, Nuvo Research, and Merck & Company (less than $10,000 each) and has received research grants from Pfizer, Nuvo Research, and Forest Laboratories.

  3. Dr. Solomon has received research grants from Amgen, Abbott, and Eli Lilly and has served as an uncompensated member of committees overseeing pain medication clinical trials sponsored by Pfizer.

*Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 75 Francis Street, PBB-B3, Boston, MA 02115

  1. †

    The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the NIH.

  2. ‡

    Dr. Lee owns stock or stock options in Merck, Novartis, and Elan and has received research grants from Forest Research Institute.

  3. §

    Dr. Clauw has received consulting fees from Jazz Pharmaceuticals, Pfizer, Eli Lilly, Forest Laboratories, Pierre Fabre Pharmaceuticals, UCB, Nuvo Research, and Merck & Company (less than $10,000 each) and has received research grants from Pfizer, Nuvo Research, and Forest Laboratories.

  4. Dr. Solomon has received research grants from Amgen, Abbott, and Eli Lilly and has served as an uncompensated member of committees overseeing pain medication clinical trials sponsored by Pfizer.

Publication History

  1. Issue published online: 27 DEC 2012
  2. Article first published online: 27 DEC 2012
  3. Accepted manuscript online: 1 NOV 2012 12:38PM EST
  4. Manuscript Accepted: 27 SEP 2012
  5. Manuscript Received: 26 MAR 2012

Funded by

  • Harvard Catalyst | The Harvard Clinical and Translational Science Center
  • National Center for Research Resources
  • National Center for Advancing Translational Sciences
  • NIH. Grant Numbers: UL1-RR-025758, AR-057578, AG-034982, AR-057920, AR-055989, AR-49880, AR-047782, AR-052403
  • Harvard University

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (170K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Étienne Dahan, Dis moi comment tu dors je te dirais pourquoi tu as mal…, Douleurs : Evaluation - Diagnostic - Traitement, 2013,

    CrossRef

  2. 2
    Inna Belfer, Nature and Nurture of Human Pain, Scientifica, 2013, 2013, 1

    CrossRef

View Full Article (HTML) Get PDF (170K)